Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $35.4 million.

  • Angiodynamics' Accounts Payables rose 185.35% to $35.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was $35.4 million, marking a year-over-year increase of 185.35%. This contributed to the annual value of $33.3 million for FY2025, which is 1181.43% down from last year.
  • Latest data reveals that Angiodynamics reported Accounts Payables of $35.4 million as of Q4 2025, which was up 185.35% from $31.9 million recorded in Q3 2025.
  • Angiodynamics' Accounts Payables' 5-year high stood at $40.4 million during Q2 2023, with a 5-year trough of $17.1 million in Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $31.6 million (2024), whereas its average is $30.3 million.
  • The largest annual percentage gain for Angiodynamics' Accounts Payables in the last 5 years was 6504.4% (2023), contrasted with its biggest fall of 1521.29% (2023).
  • Over the past 5 years, Angiodynamics' Accounts Payables (Quarter) stood at $24.2 million in 2021, then surged by 43.39% to $34.7 million in 2022, then grew by 8.54% to $37.6 million in 2023, then dropped by 7.71% to $34.7 million in 2024, then rose by 1.85% to $35.4 million in 2025.
  • Its Accounts Payables stands at $35.4 million for Q4 2025, versus $31.9 million for Q3 2025 and $33.3 million for Q2 2025.